60 Day Notice

Federal Register / Vol. 85, No. 249 / Tuesday, December 29, 2020 / Notices
cautioned that we do not redact or edit
personal identifying information from
comment submissions. You should
submit only information that you wish
to make available publicly. All
submissions should refer to File
Number SR–NYSEARCA–2020–112 and
should be submitted on or before
January 19, 2021.
For the Commission, by the Division of
Trading and Markets, pursuant to delegated
authority.28
J. Matthew DeLesDernier,
Assistant Secretary.
[FR Doc. 2020–28659 Filed 12–28–20; 8:45 am]
BILLING CODE 8011–01–P

SECURITIES AND EXCHANGE
COMMISSION
Proposed Collection; Comment
Request
Upon Written Request, Copies Available
From: Securities and Exchange
Commission, Office of FOIA Services,
100 F Street NE, Washington, DC
20549–2736

KHAMMOND on DSKJM1Z7X2PROD with NOTICES

Extension:
Form 2–E, Report pursuant to rule 609 of
Regulation E, SEC File No. 270–222,
OMB Control No. 3235–0233

Notice is hereby given that, pursuant
to the Paperwork Reduction Act of 1995
(44 U.S.C. 3501 et seq.), the Securities
and Exchange Commission (the
‘‘Commission’’) is soliciting comments
on the collection of information
summarized below. The Commission
plans to submit this existing collection
of information to the Office of
Management and Budget (‘‘OMB’’) for
extension and approval.
Rule 609 (17 CFR 230.609) under the
Securities Act of 1933 (15 U.S.C. 77a et
seq.) requires small business investment
companies and business development
companies that have engaged in
offerings of securities that are exempt
from registration pursuant to Regulation
E under the Securities Act of 1933 (17
CFR 230.601 to 610a) to report semiannually on Form 2–E (17 CFR 239.201)
the progress of the offering. The form
solicits information such as the dates an
offering commenced and was completed
(if completed), the number of shares
sold and still being offered, amounts
received in the offering, and expenses
and underwriting discounts incurred in
the offering. The information provided
on Form 2–E assists the staff in
monitoring the progress of the offering
and in determining whether the offering
has stayed within the limits set for an
offering exempt under Regulation E.
28 17

CFR 200.30–3(a)(12).

VerDate Sep<11>2014

00:55 Dec 29, 2020

Jkt 253001

The Commission estimates that, on
average, approximately one respondent
submits a Form 2–E filing each year.
The Commission further estimates that
this information collection imposes an
annual burden of four hours and
imposes an annual external cost burden
of zero.
The collection of information under
Form 2–E is mandatory. The
information provided by the form will
not be kept confidential. An agency may
not conduct or sponsor, and a person is
not required to respond to, a collection
of information unless it displays a
currently valid OMB control number.
Written comments are invited on: (a)
Whether the proposed collection of
information is necessary for the proper
performance of the functions of the
agency, including whether the
information will have practical utility;
(b) the accuracy of the agency’s estimate
of the burden of the collection of
information; (c) ways to enhance the
quality, utility, and clarity of the
information collected; and (d) ways to
minimize the burden of the collection of
information on respondents, including
through the use of automated collection
techniques or other forms of information
technology. Consideration will be given
to comments and suggestions submitted
in writing within 60 days of this
publication.
Please direct your written comments
to David Bottom, Director/Chief
Information Officer, Securities and
Exchange Commission, c/o Cynthia
Roscoe, 100 F Street NE, Washington,
DC 20549; or send an email to: PRA_
[email protected].
Dated: December 22, 2020.
Eduardo A. Aleman,
Deputy Secretary.
[FR Doc. 2020–28769 Filed 12–28–20; 8:45 am]
BILLING CODE 8011–01–P

OFFICE OF THE UNITED STATES
TRADE REPRESENTATIVE
Notice of Product Exclusion
Extensions and Additional
Modifications: China’s Acts, Policies,
and Practices Related to Technology
Transfer, Intellectual Property, and
Innovation
Office of the United States
Trade Representative (USTR).
ACTION: Notice of product exclusion
extensions and additional
modifications.
AGENCY:

In prior notices, the U.S.
Trade Representative modified the
action in the Section 301 investigation

SUMMARY:

PO 00000

Frm 00253

Fmt 4703

Sfmt 4703

85831

of China’s acts, policies, and practices
related to technology transfer,
intellectual property, and innovation by
excluding from additional duties certain
medical-care products needed to
address the COVID–19 outbreak. On
March 25, 2020, the U.S. Trade
Representative sought public comment
on additional modifications in this
investigation in order to address
COVID–19. This notice announces the
U.S. Trade Representative’s
determination to extend certain product
exclusions and to make further
modifications to remove Section 301
duties from additional medical-care
products to address COVID–19.
DATES: The product exclusion
extensions announced in this notice
will extend the exclusions through
March 31, 2021. The modifications to
exclude additional products will apply
as of January 1, 2021 until March 31,
2021. U.S. Customs and Border
Protection will issue instructions on
entry guidance and implementation.
FOR FURTHER INFORMATION CONTACT: For
general questions about this notice,
contact Associate General Counsel
Philip Butler, Assistant General
Counsels Benjamin Allen or Susie Park
Hodge, or Director of Industrial Goods
Justin Hoffmann at (202) 395–5725. For
specific questions on customs
classification or implementation of the
product exclusions identified in the
Annexes to this notice, contact
[email protected].
SUPPLEMENTARY INFORMATION:
A. Background
At the direction of the President, the
U.S. Trade Representative imposed
additional duties on products of China
in order to obtain the elimination of the
unfair and damaging acts, policies, and
practices identified in this investigation.
These additional duties were imposed
in four tranches. See 83 FR 28719 (June
20, 2018), 83 FR 40823 (August 16,
2018), 83 FR 47974 (September 21,
2018), as modified by 83 FR 49153
(September 28, 2018), and 84 FR 43304
(August 20, 2019), as modified by 84 FR
69447 and 85 FR 3741.
For each tranche, the U.S. Trade
Representative established a process by
which U.S. stakeholders could request
the exclusion of particular products
subject to the action. Additionally, the
U.S. Trade Representative later
established a process by which U.S.
stakeholders could request the
extension of particular exclusions.
Throughout the exclusion process,
USTR assessed medical necessity in
granting exclusions, consistent with its
published criteria. In addition, the U.S.

E:\FR\FM\29DEN1.SGM

29DEN1